Journal Scans
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Satraplatin Plus Prednisone in Castrate-Refractory Prostate Cancer
CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, J-M Ferrero, J-C Eymard, S Falcon, F Calabrò, N James, I Bodrogi, P Harper, M Wirth, W Berry, ME Petrone, TJ McKearn, M Noursalehi, M George, M Rozencweig
20090905
2009 Oct 5
J Clin Oncol
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
J Clin Oncol. 2009 Oct 5; Epub ahead of print, CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, J-M Ferrero, J-C Eymard, S Falcon, F Calabrò, N James, I Bodrogi, P Harper, M Wirth, W Berry, ME Petrone, TJ McKearn, M Noursalehi, M George, M Rozencweig
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Chemotherapy with docetaxel is the standard of care for patients with castrate-refractory prostate cancer (CRPC). Because of toxicity or disease progression, however, patients eventually discontinue docetaxel. Thus, an unmet therapeutic need exists for an effective second-line therapy for men with CRPC who experience progression after initial chemotherapy. Satraplatin is a novel oral platinum derivative that has demonstrated activity against prostate cancer, in drug-resistant tumor cell lines as...
